Dynavax Technologies Corporation Sustainability Profile
Dynavax Technologies Corporation, commonly referred to as Dynavax, is a prominent biopharmaceutical company headquartered in the United States. Founded in 1996, Dynavax has established itself in the immunotherapy sector, focusing on the development of innovative therapies for infectious diseases and cancer. The company is renowned for its flagship product, HEPLISAV-B, a unique hepatitis B vaccine that offers enhanced protection with a two-dose regimen. This product exemplifies Dynavax's commitment to advancing vaccine technology and improving patient outcomes. With a strong market position, Dynavax has achieved significant milestones, including successful collaborations and partnerships that bolster its research and development efforts. The company continues to expand its operational footprint, contributing to the evolving landscape of immunology and infectious disease management.
DitchCarbon Score
How does Dynavax Technologies Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dynavax Technologies Corporation's score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dynavax Technologies Corporation's reported carbon emissions
Dynavax Technologies Corporation, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges from the company, suggesting a lack of formal commitments to address carbon emissions at this time. As there is no emissions data available, it is important to note that Dynavax Technologies Corporation may still be evaluating its climate strategy or developing future initiatives. In the broader context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. However, without specific commitments or data from Dynavax, it remains unclear how they plan to engage with these industry trends.
How Carbon Intensive is Dynavax Technologies Corporation's Industry?
How Carbon Intensive is Dynavax Technologies Corporation's Location?
Dynavax Technologies Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Dynavax Technologies Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
